D3 receptor Inhibitors
2 drugsAbout D3 receptor
The D3 receptor is a dopamine receptor family member and GPCR primarily located in the brain. It modulates neuronal activity and is implicated in various central nervous system (CNS) processes.
The D3 receptor is a therapeutic target despite the lack of genetic evidence directly linking it to specific diseases. Two FDA-approved drugs targeting this receptor highlight its therapeutic potential in CNS disorders and other indications.
Two approved drugs, BARHEMSYS and ONAPGO, target the D3 receptor, both of which are small molecules. ACACIA and MDD US are the companies marketing these drugs.
Top D3 receptor Drugs
ACACIA and MDD US are the only two companies with approved drugs targeting the D3 receptor.
Low market concentration suggests relatively low barriers to entry for new competitors.
D3 receptor Drug Modality Landscape
Modalities
Routes of Administration
D3 receptor is druggable by small molecules, though no oral formulations are currently approved.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting the D3 receptor.
D3 receptor Clinical Trials 33 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on D3 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 5 | 1 | 1 | 2 | 50% |
| Phase 3 | 8 | 5 | 1 | 2 | 83% |
| Phase 4 | 14 | 12 | 2 | 0 | 86% |
Top Sponsors
By Modality
Top Conditions
D3 receptor Drug Approval Timeline (2020 - 2025)
The first drug targeting the D3 receptor was approved in 2020, with the most recent approval in 2025.
Recent approval suggests renewed interest in the target, but further approvals are needed to confirm an upward trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 26 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on D3 receptor. A trial counts if an approved drug acting on D3 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.